The role of tigecycline in the treatment of infections in light of the new black box warning

  title={The role of tigecycline in the treatment of infections in light of the new black box warning},
  author={Deepali Dixit and Rani Patel Madduri and Roopali Sharma},
  journal={Expert Review of Anti-infective Therapy},
  pages={397 - 400}
Tigecycline is an antibiotic with a broad spectrum of activity. Similar to tetracycline antibiotics, tigecycline exerts bacteriostatic activity. Earlier studies documented the safety and efficacy of tigecycline for complicated intra-abdominal and complicated skin and skin-structure infections, which led to its approval. Recent systematic reviews and meta-analyses have suggested increased risk of death in patients receiving tigecycline compared to other antibiotics. The Food and Drug… 

Re-defining tigecycline therapy.

Patients who may be treated with monotherapy, according to the official indications and dosages, from those treated with combination treatment, mostly with high dosages in the setting of nosocomial IAIs, possibly caused by MDR bacteria or as a carbapenem-sparing strategy are distinguished.

Tigecycline: Role in the Management of cIAI and cSSTI in the Indian Context

Tigecycline can be a good alternative in MDR and XDR complicated intra-abdominal and complicated skin and soft tissue infections and has potent in vitro activity against Gram-negative carbapenemase producers, except Pseudomonas aeruginosa and Proteus spp.

A Survey of Clarithromycin Monotherapy for Patients with MAC Lung Disease in Japan

High dose of tigecycline showed relatively higher therapeutic response in MDR-CR-Kp associated VAP treatment than conventional dose but, with increased rate of adverse events, which questioned its practice.

Increasing frequency of Pseudomonas aeruginosa infections during tigecycline use.

The results contribute to the need for new studies to determine the safety of tigecycline use, especially for the treatment of critically ill patients, and rational use of this antibiotic in ICU patients is essential.

Safety and Efficacy of Tigecycline in ICU Patients Based on Therapeutic Drug Monitoring.

Cmin can be a useful predictor of hepatotoxicity with a cut-off of 474.8 ng/mL in ICU patients treated with tigecycline and it is at risk of high exposure in female.

Beyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing Carbapenemases.

Treatment of CRE infections in children is particularly challenging because therapeutic options for CRE lack adequate data on dosing and safety in children, and use of unconventional combination treatment regimens, including agents to which the organism is resistant in vitro, may provide some benefit in the treatment of severe CRE infection.

Is it time to move away from polymyxins?: evidence and alternatives

Recently approved cefiderocol and phase 3 stage combination drug cefepime-zidebactam assume greater significance due to their potential to act as polymyxin-supplanting therapies in treating carbapenem-resistant infections.

Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery.

  • Ying SongLei Hu L. Tan
  • Medicine
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2018

Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients

Patients with resistant gram-negative infections may present with septic shock in the ICU and require dosage adjustments to attain optimal drug levels, which will help to maximize therapeutic efficacy while minimizing toxic effects.



Tigecycline for the Treatment of Acinetobacter Infections: A Case Series

Most patients received tigecycline therapy for the treatment of infections caused by Acinetobacter spp.

Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.

Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease

Evidence is provided that tigecycline monotherapy may be used as effectively as the comparison therapy for cSSSI, cIAIs, CAP, and infections caused by MRSA/VRE, and prudence with the clinical use of tigECyclines monotherapy in infections is required.

Tigecycline: a new glycylcycline antimicrobial agent.

  • N. Kasbekar
  • Biology, Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2006
Tigecycline is an alternative agent available for the treatment of resistant gram-negative and gram-positive infections, especially in patients with a history of a penicillin allergy or antimicrobial-related toxicities.

Efficacy and safety of tigecycline: a systematic review and meta-analysis.

Clinicians should avoid tigecycline monotherapy in the treatment of severe infections and reserve it as a last-resort drug.

Tigecycline: what is it, and where should it be used?

  • D. Livermore
  • Medicine, Biology
    The Journal of antimicrobial chemotherapy
  • 2005
Tigecycline is the first glycylcycline to be launched and is one of the very few new antimicrobials with activity against Gram-negative bacteria, likely to find a role in the treatment of infections due to multiresistant pathogens.

The emergence of clinical resistance to tigecycline.

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.